Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/172150
Sphingolipid metabolism products: potential new players in the pathogenesis of bortezomib-induced neuropathic pain
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Chemotherapy-induced peripheral neurotoxicity (CIPN) is one of the major dose-limiting adverse events of widely used drugs in both the oncologic and hematologic setting (1). Among its cardinal symptoms, neuropathic pain is frequently present (2). In particular, the incidence of bortezomib-induced peripheral neurotoxicity (BIPN) and neuropathic pain ranges from 14–45% and 5–39%, respectively, in myeloma multiple patients. BIPN is more frequently developed in pretreated patients, compared to those being chemotherapy-naïve (3,4), and this difference mostly accounts for the wide variability in the observed incidence rates. Bortezomib is the first proteasome inhibitor introduced in clinical practice. The mechanisms underlying the pathogenesis of peripheral neurotoxicity in bortezomib- treated patients are, yet, not fully elucidated (3,4).
Matèries (anglès)
Citació
Citació
ALÉ, Albert, ARGYRIOU, Andreas A. and BRUNA, Jordi. Sphingolipid metabolism products: potential new players in the pathogenesis of bortezomib-induced neuropathic pain. Annals of Translational Medicine. 2018. Vol. 6. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/172150